Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SinoMab BioScienceFRA:4VF 19 PB Ratio is 3.55 as of Sep. 10, 2026, which is 19% below its 10-year median of 4.39. GuruFocus rates FRA:4VF with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,214 Biotechnology companies, SinoMab BioScience ranks worse than 58.15% on this metric.
SinoMab BioScience Ltd stock PB Ratio (=3.81) is close to 1-year low of 3.81.
The historical rank and industry rank for SinoMab BioScience's PB Ratio or its related term are showing as below:
FRA:4VF'
s PB Ratio Range Over the Past 10 Years
Min: 1.32 Med: 4.39 Max: 18.68
Current: 3.72
During the past 9 years, SinoMab BioScience's highest PB Ratio was 18.68. The lowest was 1.32. And the median was 4.39.
FRA:4VF's PB Ratio is ranked worse than 58.15% of 1214
companies
in the Biotechnology industry
Industry Median: 2.915
vs FRA:4VF: 3.72
During the past 12 months, SinoMab BioScience's average Book Value Per Share Growth Rate was 114.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -9.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -25.40% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of SinoMab BioScience was 198.90% per year. The lowest was -38.90% per year. And the median was -24.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
SinoMab BioScience PB Ratio Related Terms
SinoMab BioScience PB Ratio Historical Data
* Premium members only.
The historical data trend for SinoMab BioScience's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SinoMab BioScience's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SinoMab BioScience PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SinoMab BioScience's PB Ratio distribution charts can be found below:
* The bar in red indicates where SinoMab BioScience's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
SinoMab BioScience (FRA:4VF) has a PB Ratio of 3.55 as of Sep. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SinoMab BioScience and its competitors. This is 19% below median its historical median of 4.39. Over the past decade, SinoMab BioScience's PB Ratio has ranged from 1.32 to 18.68. According to the industry distribution chart, SinoMab BioScience ranks #706 out of 1214 companies in the Biotechnology industry, placing it in the top 58.2%.
Is SinoMab BioScience's PB Ratio too high?
SinoMab BioScience's current PB Ratio of 3.55 is 19% below median its 10-year median of 4.39. Over the past 10 years, this metric has ranged from a low of 1.32 to a high of 18.68. The Biotechnology industry median PB Ratio is 2.92. SinoMab BioScience's value of 3.55 is 21.8% above this industry median. Based on the distribution chart, SinoMab BioScience ranks #706 out of 1214 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SinoMab BioScience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does SinoMab BioScience's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SinoMab BioScience ranks #706 out of 1214 companies for PB Ratio. This places SinoMab BioScience in the lower half of its industry. The industry median PB Ratio is 2.92. SinoMab BioScience's value of 3.55 is 21.8% above this benchmark. Historically, SinoMab BioScience's own PB Ratio has ranged from 1.32 to 18.68 over the past decade. While the company's 10-year median is 4.39 vs. the industry median of 2.92, SinoMab BioScience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,214 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SinoMab BioScience's current PB Ratio of 3.55 is 21.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SinoMab BioScience and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SinoMab BioScience's current PB Ratio is 3.55, which is 19% below median its own 10-year median of 4.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SinoMab BioScience stock overvalued right now?
SinoMab BioScience (FRA:4VF) has a current PB Ratio of 3.55. The current PB Ratio is 3.55, which is 19% below median its 10-year median of 4.39 and 21.8% above the Biotechnology industry median of 2.92. SinoMab BioScience's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For SinoMab BioScience (FRA:4VF), the current PB Ratio is 3.55 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
19GF Score
Get the complete analysis for FRA:4VF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4VF has been successfully added to your 
